These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 8508292)

  • 1. Amlodipine in the treatment of Raynaud's phenomenon.
    La Civita L; Pitaro N; Rossi M; Gambini I; Giuggioli D; Cini G; Ferri C
    Br J Rheumatol; 1993 Jun; 32(6):524-5. PubMed ID: 8508292
    [No Abstract]   [Full Text] [Related]  

  • 2. Head-to-head comparison of udenafil vs amlodipine in the treatment of secondary Raynaud's phenomenon: a double-blind, randomized, cross-over study.
    Lee EY; Park JK; Lee W; Kim YK; Park CS; Giles JT; Park JW; Shin K; Lee JS; Song YW; Lee EB
    Rheumatology (Oxford); 2014 Apr; 53(4):658-64. PubMed ID: 24352340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Raynaud's phenomenon (primary).
    Pope J
    Clin Evid; 2003 Jun; (9):1339-48. PubMed ID: 12967424
    [No Abstract]   [Full Text] [Related]  

  • 4. A randomised double-blind trial of diltiazem in the treatment of Raynaud's phenomenon.
    Kahan A; Amor B; Menkes CJ
    Ann Rheum Dis; 1985 Jan; 44(1):30-3. PubMed ID: 3882061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nicardipine in the treatment of Raynaud's phenomenon: a randomized double-blind trial.
    Kahan A; Amor B; Menkès CJ; Weber S; Guérin F; Degeorges M
    Angiology; 1987 Apr; 38(4):333-7. PubMed ID: 3555175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Nicardipine in the treatment of Raynaud's phenomenon].
    Kahan A; Amor B; Menkès CJ
    Rev Rhum Mal Osteoartic; 1987 Jun; 54(6):487-90. PubMed ID: 3303287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud's phenomenon.
    Teh LS; Manning J; Moore T; Tully MP; O'Reilly D; Jayson MI
    Br J Rheumatol; 1995 Jul; 34(7):636-41. PubMed ID: 7670782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
    Fries R; Shariat K; von Wilmowsky H; Böhm M
    Circulation; 2005 Nov; 112(19):2980-5. PubMed ID: 16275885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The treatment of severe Raynaud's phenomenon with verapamil.
    Kinney EL; Nicholas GG; Gallo J; Pontoriero C; Zelis R
    J Clin Pharmacol; 1982 Jan; 22(1):74-6. PubMed ID: 7037872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Raynaud’s phenomenon in a patient with schizophrenia and obsessive-compulsive disorder: a case report.
    Korkmaz S; Işik U; Korkmaz H
    Turk Psikiyatri Derg; 2011; 22(2):132-3. PubMed ID: 21780344
    [No Abstract]   [Full Text] [Related]  

  • 11. A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases.
    Torley HI; Madhok R; Capell HA; Brouwer RM; Maddison PJ; Black CM; Englert H; Dormandy JA; Watson HR
    Ann Rheum Dis; 1991 Nov; 50(11):800-4. PubMed ID: 1722967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Controlled double blind trial of nisoldipine in the treatment of idiopathic Raynaud's phenomenon.
    Gjørup T; Hartling OJ; Kelbaek H; Nielsen SL
    Eur J Clin Pharmacol; 1986; 31(4):387-9. PubMed ID: 3816916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A double blind placebo controlled crossover randomized trial of diltiazem in Raynaud's phenomenon.
    Rhedda A; McCans J; Willan AR; Ford PM
    J Rheumatol; 1985 Aug; 12(4):724-7. PubMed ID: 3903157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral L-arginine can reverse digital necrosis in Raynaud's phenomenon.
    Rembold CM; Ayers CR
    Mol Cell Biochem; 2003 Feb; 244(1-2):139-41. PubMed ID: 12701823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double-blind randomized trial of nitroderm TTS in the treatment of Raynaud's phenomenon.
    Nahir AM; Schapira D; Scharf Y
    Isr J Med Sci; 1986 Feb; 22(2):139-42. PubMed ID: 3081460
    [No Abstract]   [Full Text] [Related]  

  • 16. Ketanserin in the treatment of Raynaud's phenomenon associated with generalized scleroderma.
    Engelhart M
    Br J Dermatol; 1988 Dec; 119(6):751-4. PubMed ID: 3060193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double-blind, placebo-controlled study of prazosin in Raynaud's phenomenon.
    Wollersheim H; Thien T; Fennis J; van Elteren P; van 't Laar A
    Clin Pharmacol Ther; 1986 Aug; 40(2):219-25. PubMed ID: 3731684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nicardipine for the treatment of Raynaud's phenomena: a double blind crossover trial of a new calcium entry blocker.
    Rupp PA; Mellinger S; Kohler J; Dorsey JK; Furst DE
    J Rheumatol; 1987 Aug; 14(4):745-50. PubMed ID: 3312603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controlled double-blind trial of nifedipine in the treatment of Raynaud's phenomenon.
    Rodeheffer RJ; Rommer JA; Wigley F; Smith CR
    N Engl J Med; 1983 Apr; 308(15):880-3. PubMed ID: 6339921
    [No Abstract]   [Full Text] [Related]  

  • 20. [Use of nifedipine in patients with Raynaud's phenomenon].
    Rozwodowska M; Polaszewska-Muszyńska M; Ukleja-Adamowicz M; Rewakowicz M; Guzowska M; Marunowska A; Jundziłł W; Wodyńska T; Ruchalski M; Strzelecki A
    Kardiol Pol; 1987; 30 Suppl():97-105. PubMed ID: 3331405
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.